This medicine has provisional approval in Australia to treat COVID-19 in adults, 18 years and older, who do not need initiation of supplemental oxygen therapy, but who are at increased risk of progressing to need hospitalisation or of death. This approval has been granted on the basis of short term efficacy and safety data. Evidence of longer term efficacy and safety from ongoing trials continues to be gathered and submitted to the Regulatory authority for assessment.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience to your doctor, or directly at www.tga.gov.au/reporting-problems
Click below to read the PAXLOVID patient information fact sheet to learn more about why this medicine was prescribed, how often you should be taking PAXLOVID and more.
This brochure wes developed in consultation with representatives from National Aboriginal Community Controlled Health Organisation (NACCHO) and other First Nations Peoples.
Click below to learn more about this medicine.
Learn more about PAXLOVID by reading the patient factsheet which is available in different languages.
Share the eligibility checker with family and friends who you may have come into contact with while infectious with COVID-19 to check if they are eligible for anti-viral medicines.
If they have symptoms, they should get tested as early as possible and speak to their GP about COVID-19 antiviral medicines if they test positive.
Visit covidantiviral.com.au for more information
COVID-19 is caused by a virus called coronavirus, SARS-CoV-2. You can get COVID-19 through close contact with another person who has the virus.
Symptoms of COVID-19 can range from very mild (no symptoms) to severe, including illness resulting in death. In certain patients, COVID-19 may also cause some of your other medical conditions to become worse.
Older people and people of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalised for COVID-19.
The symptoms of COVID-19 can include fever, cough, and shortness of breath, which may appear 2 to 14 days after exposure. Serious illness, including breathing problems, can occur and may cause your other medical conditions to become worse.
You can find the full list of potential COVID-19 symptoms from the Australian Government here.
Australia Government, Dept of Health, Covid-19 Disease, Symptoms & Variants. https://www.health.gov.au/health-alerts/covid-19/symptoms-and-variants.
Product Expiration Date
Extended expiry for PAXLOVID has been approved. The expiry has been extended from 12 months to 24 months. The original product expiration date is listed on the product packaging, both on the carton and individual blister cards.
PAXLOVID is used to treat COVID-19 in people over 18 years who are at increased risk of progressing to hospitalisation or death.
PAXLOVID contains the active ingredients nirmatrelvir and ritonavir.
PAXLOVID is used in Australia to treat COVID-19 in adult patients with positive results of direct SARS-CoV-2 viral testing, and who are at increased risk of progression to hospitalisation or death.
You should speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about taking PAXLOVID.
Learn how and when to take this medicine.
Learn about important possible side effects.
PAXLOVID must be prescribed by a licensed healthcare professional and supplied by a Government-approved pharmacy or medical facility.
Authentic PAXLOVID, from Pfizer Australia Pty Ltd., will include the Pfizer name on the label and will be packaged in 5 aluminum push-through blister cards. Individual doses are not for sale. PAXLOVID will be packaged in a rectangular carton. The carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over the tablet, and these repeating features are seen in a contrasting matte finish.
PAXLOVID consists of tablets for a 5-day oral treatment regimen, with morning and evening doses.
Front: 3CL | Back: PFE
Front: NK | Back: No text
Pfizer is committed to patient safety in ensuring that people have accurate information about PAXLOVID, including how it is accessed and administered. We are actively monitoring for offers of illegitimate PAXLOVID to protect patients from products that might be dangerous and lead to serious or life-threatening harm.
If you suspect the product you have received may be counterfeit, contact us at 1800 675 229 or visit www.pfizermedicalinformation.com.au
For more information
This site is intended only for Australian residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.